New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

BioNTech SE Sponsored ADR

BNTX

Healthcare Biotechnology

BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.

Revenue
−16.4%
EPS
n/m
Free cash flow
n/m
Total debt
+44.4%

Quarter to September 2026, against a year earlier

81.37 0.02 −0.02%
Market cap
$20.2B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
−34.3%
Net debt / EBITDA
14.3×
Payout ratio
—

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

Of every $100 of revenue, $18.34 was left as profit. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue1.5100.0%
Cost of revenue−0.1−8.0%
Gross profit1.492.0%
Research & development−0.9−58.0%
Selling, general & admin−0.2−13.8%
Other operating costs−0.2−10.4%
Operating income0.19.7%
Other income, net+0.17.5%
Income tax0.0−2.9%
Other items+0.14.0%
Net income0.318.3%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$983M$138M$123M$1.5B
Operating income−$403M−$793M−$1.1B$144M
Net income−$226M−$665M−$994M$272M
Net margin (right axis)−23.0%−481.0%−809.6%18.3%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
1,483.87 122.78 138.22 982.92

+8 more quarters

Revenue Growth
(16.42%) (58.53%) (28.22%) (22.35%)
Cost of Revenue
118.90 112.78 83.57 377.77
Gross Profit
1,364.97 10.00 54.66 605.15
R&D Expenses
861.06 640.65 651.91 589.64
SG&A Expenses
205.45 229.98 176.50 249.84
Operating Income
143.87 (1,102.36) (792.95) (403.16)
Non-operating Interest Expenses
9.55 9.19 13.11 5.86
Non-operating Income/Expense
111.65 103.95 128.04 111.79
EBT
255.52 (998.41) (664.90) (291.37)
Income Tax Provision
43.16 (44.07) (42.37) 83.55
Income after Tax
212.36 (954.34) (622.54) (374.92)
Net Income Common
212.36 (954.34) (622.54) (374.92)
EPS (Basic)
0.85 (3.77) (2.46) (1.46)
EPS (Diluted)
0.84 (3.77) (2.46) (1.46)
Shares (Basic, Weighted)
249.34 253.34 253.27 241.70
Shares (Diluted, Weighted)
252.75 253.34 253.27 241.70
Gross Margin
91.99% 8.14% 39.54% 61.57%
EBIT Margin
9.70% (897.82%) (573.67%) (41.02%)
EBT margin
17.22% (813.16%) (481.03%) (29.64%)
Net Profit Margin
14.31% (777.27%) (450.38%) (38.14%)
EBITDA
521.82 (793.90) (650.98) (224.88)
EBIT
143.87 (1,102.36) (792.95) (403.16)
Income from Continuous Operations
212.36 (954.34) (622.54) (374.92)
Consolidated Net Income/Loss
212.36 (954.34) (622.54) (374.92)
EPS (Basic, from Continuous Ops)
0.85 (3.77) (2.46) (1.54)
EPS (Diluted, from Cont. Ops)
0.84 (3.77) (2.46) (1.54)
EPS (Basic, Consolidated)
0.85 (3.77) (2.46) (1.54)
EPS (Diluted, Consolidated)
0.84 (3.77) (2.46) (1.54)
Shares (Diluted, Average)
252.74 253.33 253.29 244.00
EBITDA Margin
35.17% (646.59%) (470.96%) (22.88%)
Operating Cash Flow Margin
(9.74%) 12.58% (356.48%) 35.07%

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026